A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- NON RANDOMIZED · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 20
- Population
- ALL · 18 Years to 80 Years
- Duration
- 2014-11-01 to 2015-06-01
- Intervention
- MTP-131
- Comparator
- Not reported
- Outcomes measured
- Incidence and severity of systemic and ocular adverse events — From Baseline to Day 28; Change from Baseline in vital sign measurements — From Baseline to Day 28; Change from Baseline in best corrected visual acuity (BCVA) as measured with the early treatment diabetic retinopathy s…; Change from Baseline in slit lamp examinations — From Baseline to Day 28; Change from Baseline in intraocular pressure — From Baseline to Day 28; Change from Baseline in dilated fundoscopic examinations — From Baseline to Day 28; Change from Baseline in central subfield thickness — From Baseline to Day 28; Change in central subfield thickness — From Baseline to Day 28; Change from Baseline in widefield angiography — From Baseline to Day 28; Change from Baseline in fundus autofluorescence pattern including the occurrence of and aggregate size of areas of macu…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.